Drug Profile
Arformoterol
Alternative Names: (R,R)-eformoterol; (R,R)-formoterol; Arformoterol tartrate; Arformoterol tartrate inhalation; Brovana; Eformoterol - Sumitomo Pharma America; Formoterol - Sumitomo Pharma America; R,R-eformoterol; R,R-formoterolLatest Information Update: 05 Nov 2023
Price :
$50
*
At a glance
- Originator Sepracor
- Developer Sumitomo Pharma America
- Class Antiasthmatics; Ethanolamines; Small molecules
- Mechanism of Action Beta 2 adrenergic receptor agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Marketed Chronic obstructive pulmonary disease
- Discontinued Asthma
Most Recent Events
- 01 Nov 2014 Discontinued - Phase-II for Asthma (In children) in USA (Inhalation)
- 08 Jul 2014 Final efficacy and adverse events data from a phase III trial in Chronic obstructive pulmonary disease released by Sunovion Pharmaceuticals
- 30 Oct 2013 Final adverse events data from a phase III long-term safety trial in Chronic obstructive pulmonary disease released by Sunovion Pharmaceuticals